Cerus Corporation (CERS) vs Bright Minds Biosciences Inc. (DRUG)

A side-by-side comparison of Cerus Corporation and Bright Minds Biosciences Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare

Total return — CERS vs DRUG

growth of $100 · dividends reinvested · last 6y
CERS -61.7% (-14.8%/yr)DRUG +84.4% (+10.7%/yr)DRUG compounded faster over this window
0100200300Start $10020222023202420252026$38$184
CERS DRUG

CERS vs DRUG: by the numbers

  • •DRUG is the larger company ($487M vs $472M market cap).
  • •Both run net losses; DRUG's is the smaller (0.00% vs -3.06% net margin).

Metrics side by side

Valuation

MetricCERSDRUG
P/S ratio2.13N/A
P/B ratio6.732.25
EV / EBITDA8036.17N/A

Profitability

MetricCERSDRUG
Gross margin52.05%0.00%
Operating margin-0.73%0.00%
Net margin-3.06%0.00%
ROE-9.69%-8.21%
ROIC-1.08%-13.15%

Growth (annualized)

MetricCERSDRUG
Revenue CAGR (5Y)15.74%N/A
Total return CAGR (5Y)-17.30%6.76%

Frequently asked

How have CERS and DRUG total returns compared?
Over the past 5 years, CERS delivered -17.30% and DRUG delivered 6.76% annualized total return. Past performance doesn't predict future results.

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.